SARS-CoV-2 and Multiple Sclerosis: Not All Immune Depleting DMTs are Equal or Bad

Ann Neurol. 2020 Jun;87(6):794-797. doi: 10.1002/ana.25770.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Betacoronavirus* / drug effects
  • Betacoronavirus* / immunology
  • COVID-19
  • Coronavirus Infections / drug therapy*
  • Coronavirus Infections / immunology
  • Humans
  • Immunosuppressive Agents / adverse effects
  • Immunosuppressive Agents / therapeutic use*
  • Multiple Sclerosis / drug therapy*
  • Multiple Sclerosis / immunology
  • Pandemics
  • Pneumonia, Viral / drug therapy*
  • Pneumonia, Viral / immunology
  • Practice Guidelines as Topic / standards*
  • SARS-CoV-2
  • Severe Acute Respiratory Syndrome / drug therapy
  • Severe Acute Respiratory Syndrome / immunology
  • Severe acute respiratory syndrome-related coronavirus / drug effects
  • Severe acute respiratory syndrome-related coronavirus / immunology

Substances

  • Immunosuppressive Agents